"sbir phase i new 3D hubiogel culture system for cancer stem cells expansion & analysis"

Ended Definitive Contract Awarded Last action

Contract number
HHSN261201500066C
Awardee
Awarding agency
Obligated
$219,812

Award facts

Contract value 100% obligated
$219,812.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 13 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Birmingham, AL 35205, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action 2 $0
Other Administrative Action 1 · Vivo biosciences INC:1105872 [15-068311] $0
Original award $219,812

About this award

The National Cancer Institute awarded a Firm Fixed Price Definitive Contract to Vivo Biosciences, Inc. for the "SBIR PHASE I NEW 3D HUBIOGEL CULTURE SYSTEM FOR CANCER STEM CELLS EXPANSION & ANALYSIS" project. The contract has a ceiling value of $219,812.00 and the ultimate completion date is July 21, 2016. This is a Small Business Innovation Research (SBIR) Phase I contract, which supports early-stage research and development of innovative technologies. The contract does not have a set-aside designation.

Quick answers

Who was awarded contract HHSN261201500066C?

HHSN261201500066C was awarded to Vivo Biosciences, Inc. by National Cancer Institute (National Institutes of Health) on September 22, 2015.

How much is contract HHSN261201500066C worth?

The government has obligated $219,812 on HHSN261201500066C.

Was contract HHSN261201500066C competed?

The extent of competition for HHSN261201500066C was full and open competition. The government received 13 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award